



FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP 600 CONGRESS AVENUE, SUITE 2400 AUSTIN, TEXAS 78701-3271 WWW.FULBRIGHT.COM RECEIVED

AUG 2 2 2007

TECH CENTER 1600/2900

DIRECT DIAL: TELEPHONE: FACSIMILE:

(512) 536-3184 (512) 474-5201

(512) 536-4598

STEVEN L. HIGHLANDER
PARTNER
SHIGHLANDER@FULBRIGHT.COM

August 15, 2002

CERTIFICATE OF MAILING 37 C.F.R 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 for the date below:

August 15, 2002

Date

Steven L. Highlander

Commissioner for Patents Washington, DC 20231

Re: U.S. Patent Application No. 09/872,852 entitled "HUMAN BETA-DEFENSIN-3"

(HBD-3), A HIGHLY CATIONIC BETA-DEFENSIN ANTIMICROBIAL PEPTIDE"

by Paul B. McCray, Jr. et al. Our Reference: IOWA:031US Client Reference: UIRF:M0-49

Sir:

Enclosed for filing in the above-referenced patent application is a Supplemental Information Disclosure Statement, Form PTO-1449, and references (A1, B5-B6).

No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/IOWA:031US.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectably submitted,

Steven L. Highlander Reg. No. 37,642

SLH/cmb Encl.: as noted 25197861.1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ication of:

Paul B. McCray, Jr. et al.

Serial No.: 09/872,852

Filed: June 1, 2001

For: HUMAN BETA-DEFENSIN-3 (HBD-3), A HIGHLY CATIONIC BETA-DEFENSIN

ANTIMICROBIAL PEPTIDE

Group Art Unit: 1646

Examiner: Unknown

Atty. Dkt. No.: IOWA:031U

CERTIFICATE OF MAILING

37 C.F.R 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, of the date

below:

August 15, 2002

Date

Steven L. Highlander

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Washington, D.C. 20231

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R §§ 1.97(g), (h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Supplemental Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R § 1.97(b). No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is hereby authorized to deduct said fees from Fulbright &

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,

Steven Highlander

Reg. No. 37,642

Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P. 600 Congress Avenue, Suite 2400 Austin, Texas 78701 (512) 474-5201

Jaworski Deposit Account No.: 50-1212/IOWA:031US.

Date:

August 15, 2002

List of Patents and Publications for Applicant's NFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				IOWA:031U	Atty. Docket No. Serial N IOWA:031US 09/872,8		.852	
				1	Applicant Paul B. McCray, Jr. et al. Filing Date: June 1, 2001 Patent Documents See Page 1 Group: 1646 Other Art See Page 1			
				Filing Date: June 1, 2001	_			
		Documents	Foreig	n Patent Documer	its		ther Art	
		Page 1	<u></u>	See Page 1			See Page 1	
			U.S. Pa	tent Docum	ents			
Exam Init.	. Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.	
di	2 A1	6,399,370 B1	6/4/02	Wilson et al.	435	325	1/12/99	
		F	oreign F	Patent Docu	ments		<u> </u>	
Exam Init.	. Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No	
	B5	DE 10033505.5	7/1100	Germany			No	
W/K	B6	WO 02/04487	1/17/02	PCT			Yes 1 Alo	
	Other	Art (Includin	g Autho	r, Title, Dat	e Pertin	ent Pag		
Exam Init.	Ref. Des.			Citatio	on			
_								

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH



FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP 600 CONGRESS AVENUE. SUITE 2400 AUSTIN, TEXAS 78701-3271 WWW.FULBRIGHT.COM

STEVEN L. HIGHLANDER PARTNER SHIGHLANDER@FULBRIGHT.COM DIRECT DIAL: TELEPHONE:

(512) 536-3184 (512) 474-5201

FACSIMILE:

(512) 536-4598

July 24, 2002

RECEIVED

AUG 0 1 2002

CERTIFICATE OF MAILING 37 C.F.R 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Clase-Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 of the date below:

TECH CENTER 1600/290 Puly 24, 2002

Highlander

Commissioner for Patents Washington, DC 20231

Re:

U.S. Patent Application No. 09/872,852 entitled "HUMAN BETA-DEFENSIN-3

(HBD-3), A HIGHLY CATIONIC BETA-DEFENSIN ANTIMICROBIAL PEPTIDE"

by Paul B. McCray, Jr. et al. Our Reference: IOWA:031US Client Reference: UIRF:M0-49

Sir:

Enclosed for filing in the above-referenced patent application is a Supplemental Information Disclosure Statement, Form PTO-1449, and references (B1-B4).

No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/IOWA:031US.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,

Steven 🔥 Highlander Reg. No. 37,642

SLH/cmb Encl.: as noted 25189868.1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Paul B. McCray, Jr. et al

Serial No.: 09/872,852

Filed: June 1, 2001

For: HUMAN BETA-DEFENSIN-3 (HBD-3), A HIGHLY CATIONIC BETA-DEFENSIN ANTIMICROBIAL PEPTIDE

RECEIVED

Group Art Unit: 1646

AUG 0 1 2002

Examiner: Unknown

TECH CENTER 1600/2900

Atty. Dkt. No.: IOWA:031US

CERTIFICATE OF MAILING 37 C.F.R 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, or me date

below:

July 24, 2002

Date

Steven L. Highlander

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Washington, D.C. 20231

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R §§ 1.97(g), (h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Supplemental Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R § 1.97(b). No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/IOWA:031US.

Applicants respectfully request that the listed documents be made of record in the present case.

especifully submitted,

Steven L. Highlander

Reg. No. 37,642 Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P. 600 Congress Avenue, Suite 2400 Austin, Texas 78701 (512) 474-5201

Date:

July 24, 2002

								
Form PTO-1449 (modified)				Atty. Docket		1	l No.	
					IOWA:031US		72,852	
		d Publications for	- •	Applicant	I			
(Use several sheets if necessary) Foreign P				Paul B. McCi	Paul B. McCray, Jr. et al.			
				Filing Date:	Filing Date: G			
				June 1, 2001			Group: 1646	
J.	S. Patent	Documents	Foreig	n Patent Documen	ts	(Other Art See Page 1	
ADEMAS U.	See F	age 1		See Page 1				
			U.S. Pa	tent Docum	ents			
Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.	
_]			}		<u> </u>	
			oroian C	etant Deau	monto		<u></u>	
		F	oreign F	atent Docui	ments			
Exam. Init.	Ref. Des.	Pocument Number	oreign F	Country	Clas		Translation Yes/No	
_	_ `	Document				s Sub		
_	Des.	Document Number	Date	Country		s Sub		
_	Des.	Document Number WO 00/46245	Date 8/10/00	Country		s Sub		
_	B1 B2	Document Number WO 00/46245 WO 02/04487	8/10/00 1/17/02	Country PCT PCT		s Sub		
Init.	B1 B2 B3 B4	Document Number WO 00/46245 WO 02/04487 WO 02/09738 WO 99/13080	8/10/00 1/17/02 2/7/02 3/18/99	PCT PCT PCT PCT	Clas	s Sub Class	Yes/No	
Init.	B1 B2 B3 B4	Document Number WO 00/46245 WO 02/04487 WO 02/09738	8/10/00 1/17/02 2/7/02 3/18/99	PCT PCT PCT PCT	Clas	s Sub Class	Yes/No	

RECEIVED

AUG 0 1 2002

TECH CENTER 1600/2900

25189853.1		
EXAMINER:	OBO Pobinion DATE CONSIDERED: 10/38/03	_
	FERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH RMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

1646

LBRIGHT & JAWORSKI L.L.P.

REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE. SUITE 2400
AUSTIN. TEXAS 78701

STEVEN L. HIGHLANDER PARTNER

TELEPHONE: 512/4

FACSIMILE: 512/536

INTERNET ADDRESS: SHIGHLANDER@FULBRIGHT.COM

DIRECT DIAL: 512/536-3184

RECEIVED

HOUSTON
WASHINGTON, D.C.
AUSTIN
SAN ANTONIO
DALLAS
NEW YORK
LOS ANGELES
MINNEAPOLIS
LONDON
HONG KONG

APR 1 1 2002

April 4, 2002

TECH CENTER 1600/2900 FILE: IOWA:031US

CERTIFICATE OF MAILING 37 C.F.R 18

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mall in an envelope addressed to: 20mmissioner for Patents, Washington, DC 20237, an the date

below:

April 4, 2002 Date

Stayen L Highlander

Commissioner for Patents Washington, DC 20231

RE:

SN 09/872,852 "HUMAN BETA-DEFENSIN-3 (HBD-3), A HIGHLY CATIONIC

BETA-DEFENSIN ANTIMICROBIAL PEPTIDE" - Paul B. McCray, Jr., et al. (Client

Reference: URIF:M0-49)

Sir:

Enclosed for filing in the above-referenced patent application is a Supplemental Information Disclosure Statement, Form PTO-1449, and references (C15).

No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10104720/SLH.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

espectfully submitted,

Steven L. Righlander Reg. No. 37,642

SLH/cmb

Encl: as noted

THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

In re Application of:

Paul B. McCray, Jr., et al.

Serial No.: 09/872,852

Filed: June 1, 2001

For: HUMAN BETA-DEFENSIN-3 (HBD-3), A HIGHLY CATIONIC BETA-DEFENSIN

ANTIMICROBIAL PEPTIDE

Group Art Unit: 1646

APR 1 1 2002

Examiner: Unknown

TECH CENTER 1600/2900

Atty. Dkt. No.: IOWA:031US/SLH

CERTIFICATE OF MAILING 37 C.F.R 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Coronlasioner for Patents, Washington, DC 20201, on the date

below:

April 4, 2002

Date

Steven ... Highlander

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Washington, D.C. 20231

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R §§ 1.97(g), (h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Supplemental Information Disclosure Statement is being filed prior to the

receipt of a first Official Action reflecting an examination on the merits, and hence is believed to

be timely filed in accordance with 37 C.F.R § 1.97(b). No fees are believed to be due in

connection with the filing of this Supplemental Information Disclosure Statement, however,

should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to

these materials, the Commissioner is hereby authorized to deduct said fees from Fulbright &

Jaworski Deposit Account No.: 50-1212/10104720/SLH.

Applicants respectfully request that the listed documents be made of record in the present

case.

Respectfully submitted,

Steven L. Highlander

Attorney for Applicants

Reg. No. 37,642

FULBRIGHT & JAWORSKI L.L.P. 600 Congress Avenue, Suite 2400 Austin, Texas 78701 (512) 474-5201

Date: April 4, 2002

RECEIVED APR 1 1 2002

Page 1 of 1 Atty. Docket No. Serial No. Form PTO-1449 (modified) TEGH CENTER 1600/2900 09/872,852 IOWA:031US/SLH Applicant List of Patents and Publications for Applicant's Paul B. McCray, Jr., et al. NFORMATION DISCLOSURE STATEMENT Filing Date: Group: APR 0 9 2002 (Use several sheets if necessary) 1646 June 1, 2001 Other Art **Foreign Patent Documents Patent Documents** See Page 1 See Page 1 See Page 1

			U.S. Pa	tent Docum	ents		
Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
		<u> </u>	oreign F	Patent Docu	ments		
Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	Other A	Art (Includi	ng Autho	or, Title, Dat	e Pertin	ent Pag	ges, Etc.)
Exam. Init.	Ref. Des.			Citati	on		
TX	C15	Co-pending U.S. August 18, 2000		ation Serial Numb	er 09/642,744	by Brian F	. Tack et al., filed

25151217.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAY LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.



INTERNET ADDRESS: SHIGHLANDER@FULBRIGHT.COM

DIRECT DIAL: 512/536-3184

October 29, 2001

FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP 600 CONGRESS AVENUE, SUITE 2400 AUSTIN, TEXAS 78701

RECEIVED

DEC 0 4 2001

TECH CENTER 1600/2900

OP 1646.

HOUSTON
WASHINGTON, D.C.
AUSTIN
SAN ANTONIO
DALLAS
NEW YORK
LOS ANGELES
MINNEAPOLIS
LONDON
HONG KONG

FILE: IOWA:031US

CERTIFICATE OF MAILING 37 C.F.R 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Compressioner for Patents, Washington, DC 20201) on the date below:

_ . . . _ . .

October 29, 2001

Date Steven L. Highlander

Commissioner for Patents Washington, DC 20231

RE: SN 09/872

SN 09/872,852 "HUMAN BETA-DEFENSIN-3 (HBD-3), A HIGHLY CATIONIC

BETA-DEFENSIN ANTIMICROBIAL PEPTIDE" - Paul B. McCray, Jr., et al. (Client Reference: URIF:MO-49)

Sir:

Enclosed for filing in the above-referenced patent application is an Information Disclosure Statement, Form PTO-1449, and references (C1-C14).

No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10104720/SLH.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,

Steven I.) Highlander Reg. No. 37,642

SLH/cmb

Encl: as noted

2001 N

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

in Page Ancation of:

Paul B. McCray, Jr., et al.

Serial No.: 09/872,852

Filed: June 1, 2001

For: HUMAN BETA-DEFENSIN-3 (HBD-3), A HIGHLY CATIONIC BETA-DEFENSIN

ANTIMICROBIAL PEPTIDE

Group Art Unit: 1646

Examiner: Unknown

Atty. Dkt. No.: IOWA:031US/SLH

CERTIFICATE OF MAILING 37 C.F.R 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on the date

below:

October 29, 2001

Date

Keven I. Highlander

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Washington, D.C. 20231

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit

Account No.: 50-1212/10104720/SLH.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,

Steven L.)Highlander

Reg. No. 37,642 Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P. 600 Congress Avenue, Suite 2400 Austin, Texas 78701 (512) 474-5201

Date:

October 29, 2001

Form F							
- 4,	TO-144	9 (modified)		Atty. Docket	No.	Serial	No.
				IOWA:031US	SISLH	09/872	2,852
5 List of I	atents ar	nd Publications for	r Applicant's	Applicant		•	
e 7				Paul B. McCr	ay, Jr., et	al.	
例	PRMATIC	ON DISCLOSURE S	STATEMENT				
3 2001				Filing Date:		Group):
•	(Use s	several sheets if necess	ary)	June 1, 2001		1646	
, Ø.	S. Patent	Documents	Foreign	Patent Document	ts	0	ther Art
MARKO	See F	Page 1	1	See Page 1]	S	ee Page 1
							
			U.S. Pat	ent Docume	ents		·
Exam.	Ref.	Document	Date	Name	Class	Sub	Filing Date of
Init.	Des.	Number	}		}	Class	App.
						}	
		F	Foreign P	atent Docur	nents		
Exam.	Ref.	Document	Date	Country	Class	Sub	Translation
Init.	Des.	Number				Class	Yes/No
(Other .	Art (Includi	ng Autho	r, Title, Date	Perti	nent Pag	ges, Etc.)
Exam.	Ref.			Citatio	n		
lnit.	Des.	1					
init.	Des.	Gallo, et al., "An Dermatol, 111(5)		tides: an emerging 3.	concept in	cutaneous b	iology," J. Invest
init.		Dermatol, 111(5)):739-743, 1998	3. 			ns Immun, 10:41-44,
init.	CI	Dermatol, 111(5) Ganz and Lehrer, 1998. Hamil et al., "HE):739-743, 1998 , "Antimicrobia Ε2β and HE2γ,	3. 	orates," <i>Cu</i>	rrent Opinion	ns Immun, 10:41-44, mily of androgen-
init.	C1	Dermatol, 111(5) Ganz and Lehrer, 1998. Hamil et al., "HE regulated protein Harder et al., "Sh	2β and HE2γ, is in the human,	3. al peptides of verteb	rates," Cu epididym 41(3): 124	rrent Opinion is-specific fa 5-1253, 2000 acoding hum	ns Immun, 10:41-44, mily of androgen-). an β-Defensin-2
init.	C2 C3	Dermatol, 111(5) Ganz and Lehrer, 1998. Hamil et al., "HE regulated protein Harder et al., "Sh (DEFB2) to chros	2β and HE2γ, is in the human, nort communications mosome region very of new human.	Il peptides of verteb new members of an "Endocrinology, 1 ation—Mapping of	rates," Cu epididym 41(3): 124 the gene en omics, 46:4	rrent Opinion is-specific fa 5-1253, 2000 acoding hum 172-475, 199	ns Immun, 10:41-44, mily of androgen-). an β-Defensin-2 7.
init.	C2 C3	Dermatol, 111(5) Ganz and Lehrer, 1998. Hamil et al., "HE regulated protein Harder et al., "Sh (DEFB2) to chrose 263:211-218, 200	2β and HE2γ, is in the human, nort communications are region very of new human.	B. al peptides of vertebone members of an embers of an	rates," Cu epididym 41(3): 124 the gene en omics, 46:4	rrent Opinion is-specific fa 5-1253, 2000 acoding hum 172-475, 199 mics-based a	ns Immun, 10:41-44, mily of androgen-). an β-Defensin-2 7.
Init.	C1 C2 C3 C4 C5	Dermatol, 111(5) Ganz and Lehrer, 1998. Hamil et al., "HE regulated protein Harder et al., "Sh (DEFB2) to chrose 263:211-218, 200 Kirchhoff et al., cultures," Mol. Regulated al., "Reg	2β and HE2γ, s in the human, nort communications are region very of new human, eprod. Dev., 56 ion-specific variance of the communication of the human, and the human, and the communication of the human, and the h	s. al peptides of vertebranew members of an ew members of an extra man β-defensins using man β-defensins using modulated by and ex26-33, 2000.	repididym 41(3): 124 the gene en omics, 46:4 ing a genor	is-specific far 5-1253, 2000 acoding hum 172-475, 199 mics-based ag	mily of androgen- an β-Defensin-2 pproach," Gene, ididymis as revealed

EXAMINER: DATE CONSIDERED: 130 83

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

				1 age 2	UL Z
•	Form PTO-1449 (modified)		Atty. Docket No.	Serial No.	
			IOWA:031US/SLH	09/872,852	
OIF	SORMATION DISCLOSURE		Applicant Paul B. McCray, Jr., e	et al.	
E .	3 2001 (Use several sheets if neces	ssary)	Filing Date: June 1, 2001	Group: 1646	
Ex.	See Page 1	Foreign 1	Patent Documents	Other Art	_
RADI	See Page 1		See Page 1	See Page 1	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation				
**E	C9	Mathews et al., "Production of β-defensin antimicrobial peptides by the oral mucosa and slivary glands," Infect Immun., 67(6):2740-2745, 1999.				
	C10	Nilsson et al., "Patient education for adults with chronic eczema," Dermatol Nurs, 11(2):117-122, 1999.				
	CII	Oren and Shai, "Mode of action of linear amphipathic α-helical antimicrobial peptides," Biopolymers, 47:451-463, 1998.				
	C12	Osterhoff et al., "Molecular cloning and characterization of a novel human sperm antigen (HE2) specifically expressed in the proximal epididymis," Biol Reprod, 50:516-525, 1994.				
	C13	Russell et al., "Coordinate induction of two antibiotic genes in tracheal epithelial cells exposed to the inflammatory mediators lipopolysaccharide and tumor necrosis factor alpha," Infect Immun., 64(5):1565-1568, 1996.				
V	Ç14	Singh et al., "Production of β-defensins by human airway epithelia," Proc. Natl. Acad. Sci USA., 95:14961-14966, 1998.				

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.